The Economic Times

Donald Trump raised stakes in drug companies gaining from medicare exemptions, say Democrats

Investments in pharmaceutical companies on behalf of Donald Trump saw a significant increase after returning to the White House. His portfolio reportedly grew from $1.7 million in 2024 to as much as $56.2 million by late 2025. A large portion of this growth involved investing in stocks benefiting from exemptions to Medicare price negotiations. Notably, purchases included $2.55 million in shares just before signing favorable legislation.